The nonsense-mediated decay (NMD) pathway is an mRNA surveillance system that typically degrades transcripts containing premature termination codons (PTCs) in order to prevent translation of unnecessary or aberrant transcripts. Failure to eliminate these mRNAs with PTCs may result in the synthesis of abnormal proteins that can be toxic to cells through dominant-negative or gain-of-function effects. Recent studies have expanded our understanding of the mechanism by which nonsense transcripts are recognized and targeted for decay. Here, we review the physiological role of this surveillance pathway, its implications for human diseases, and why knowledge of NMD is important to an understanding of genotype -phenotype correlations in various genetic disorders.
Introduction
The elucidation of nonsense-mediated decay (NMD) as an RNA surveillance system is a relatively recent event. Studies in yeast and other model organisms have enumerated specific molecular details that provide some insight into mechanisms whereby a transcript that contains a premature termination codon (PTC) is recognized by NMD factors and rapidly degraded, thus eliminating abnormal transcripts. 1 Genetic screens in Saccharomyces cerevisiae and
Caenorhabditis elegans have identified key NMD factors such as UPF1 -3 (up-frameshift proteins 1, 2 and 3) in yeast and smg1 -7 (suppressor with morphogenetic effects on genitalia 1 -7) in C. elegans that play an essential role in NMD. 2 -5 The importance of UPF genes for higher life forms is highlighted by the observation that the basic function of these proteins is conserved in all eukaryotes. The UPF1-3 proteins (also known as SMG2-4 in C. elegans) are conserved from yeast to humans, whereas SMG1, SMG5 and SMG6 have orthologs in higher eucaryotes but not in S. cerevisiae. 6 Deletion or suppression of Upf genes eliminates NMD and prevents the normally rapid decay of transcripts containing nonsense or frameshift mutations in eucaryotes. 3, 7, 8 The exact molecular mechanism for NMD in higher eucaryotes is still being elucidated. In mammalian NMD, an intron apparently functions as a second signal for triggering NMD by leaving a 'mark' on the mRNA at the exon -exon junction as a consequence of the splicing event. This mark known as the exon-junction complex (EJC) 9, 10 enables the NMD RNA surveillance pathway to differentiate between PTCs and normal stop codons present in the last exon ensuring the degradation only of transcripts containing nonsense codons that are followed by an intron. 11, 12 Evidence from a number of studies suggests that during the initial rounds of translation, referred to as the 'pioneer round', 13 the translating ribosome pauses at the PTC. Release factors eRF1 and eRF3, which associate with the terminating ribosome, recruit UPF1, which subsequently makes contact with UPF2 and UPF3, which are bound to EJCs. 9, 14 Formation of this complete 'surveillance complex', containing UPF1-3 is believed to initiate mRNA degradation by NMD (for a review see Lejeune and Maquat 15 ). In normal transcripts, in which the termination codon occurs in the final exon, all EJCs are displaced by the translating ribosomes. Thus, the complete surveillance complex cannot form during translation termination because of the absence of UPF2 and UPF3, thus NMD is avoided. One of the main roles of mammalian NMD is to regulate the expression of many physiological transcripts. 2, 15, 16 Given the number and diversity of transcripts regulated by NMD, the mammalian NMD machinery may have evolved into a more complex and efficient system in comparison to other lower model organisms. Recently, it has been reported that Upf1 is not only essential to NMD but also is required both for rapid degradation of histone mRNAs and reducing the half-life of normal mRNAs containing a Staufen binding site. 17, 18 This has created a unique dependence of mammals on the NMD pathway and its key factors. The mammalian NMD surveillance system cannot distinguish PTCs in the penultimate exon that are located less than B55 base pairs (bp) from the final intron. The 'B55 bp rule' for the 3 0 end of the penultimate exon is believed to reflect the location of the EJC on spliced mRNAs; a translocating ribosome would displace an EJC upstream of the last exon -exon junction before the ribosome could recognize a stop codon located less than B55 nucleotide from the exon -exon junction. 9 However, there are several genes whose mRNA degradation appears to show exceptions to this rule, including hexoseaminidase A (HEXA), 19 MPZ, encoding myelin protein zero, 20 HNF-1b (hepatocyte nuclear factor-1b), 21 and the T-cell receptor (TCR) 22 genes of the cellular immune system. The failure of some genes to follow the 'B55 boundary rule' suggest that either alternative or additional signals may exist other than the EJC positioned at the B20 -B24 nucleotide upstream of the exon -exon junction or potentially an entirely different protein complex at the exon -exon junction could be utilized for some genes to trigger NMD. 22 As a consequence, the inability to differentiate nonsense codon mutations in the last and 3 0 end of the penultimate exon from the normal termination codon can result in the stable translation of mRNAs that contain PTCs located within these 'protected' regions. Thus, mRNAs with nonsense codons present in such positions can escape the NMD pathway (Figure 1 ). Such an 'escape from NMD surveillance' may cause expression of large amounts of aberrant truncated proteins with potential dominantnegative or gain-of-function effects in cells. This latter mechanism may be particularly relevant to 'disease genes' with large last exons.
There are many well-studied examples of human phenotypes resulting from nonsense or frameshift mutations that are modulated by NMD (Tables 1 -3 ). The phenotypes of genetic diseases are likely to be frequently affected by NMD as nonsense and frameshift mutations are present in approximately one-third of point mutations that cause human genetic disorders. 23, 24 Here, we review the roles for the NMD RNA surveillance pathway in altering the inheritance pattern for a disease trait and in modifying the ultimate phenotype for selected human diseases. (Table 1) . Mutations in the muscle chloride channel CLCN1 gene, which regulates the electrical excitability of the skeletal muscle membrane, can cause either dominant or recessive myotonia congenita. The autosomal recessive myotonia congenita (Becker disease) can be caused by compound heterozygous mutations, such as premature stop codons in an upstream exon of one allele in combination with a mutation in the other allele, causing a total loss-offunction in CLCN1. However, a less common Thomsen disease, the autosomal-dominant congenital myotonia, can be caused by PTCs in the last exon in one allele as such mutations may escape NMD and function as dominant-negative alleles. 27 Interestingly, nonsense and frameshift mutations in ROR2, encoding a receptor tyrosine kinase, result in both an autosomal-recessive form of Robinow syndrome (RRS) and a dominant form of Brachydactyly type B (BDB). 30, 31 RRS is a severe skeletal dysplasia with shortening of the limbs, segmental defects of the spine, brachydactyly and a dysmorphic facial appearance, whereas BDB is characterized by distal phalanges and nail aplasia. 30, 32 No functional mechanisms have yet been delineated to explain effectively the association between mutation and different mode of inheritance causing different phenotypes (ie genotype/phenotype correlations). However, most mutations in ROR2 that results in premature stop codons in downstream exons appear to result in BDB segregating as an autosomal-dominant trait, whereas PTCs in upstream exons result in RRS. Previous studies 33 have revealed decreased ROR2 mRNA levels in fibroblast cell lines of patients with PTCs causing the autosomal-recessive RRS, suggesting that these truncating mutations could possibly trigger the NMD pathway. By analogy to and inference from the b-globin gene observations, the decrease/absent mutant mRNA levels can cause a distinct recessive mode of inheritance. Likewise, truncating mutations in ABCC6, a member of ATP-binding cassette (ABC) transporter superfamily C, can potentially cause different patterns of inheritance (autosomal-recessive and a less common autosomaldominant form) for Pseudoxanthoma elasticum (PXE). NMD has been hypothesized to contribute to clinical variability in the expression of PXE. 34 However, there has not been any direct evidence of its role in this disorder or as a mechanism to explain the phenotype or inheritance pattern from the genotype, or vice versa. This uncertainty has recently brought the existence of the autosomaldominant mode of inheritance of PXE into question. 35 
NMD and human Mendelian disease

Distinct phenotypic traits conveyed by allelic truncating mutations
Although in theory all nonsense and frameshift mutations resulting in PTC are natural targets of the NMD RNA surveillance system, it is likely that NMD is not the only pathway actually responsible for mRNA stability/ degradation and thus modulating disease severity. Figure 2 ). As in SOX10, different truncating mutations in MPZ are responsible for distinct clinical entities that each affect the myelin of the peripheral nervous system. 20 These neuropathies include early-onset congenital hypomyelinating neuropathy (CHN) and Dejerine -Sottas neuropathy (DSN) as well as the less severe, adult onset Charcot -Marie -Tooth disease type 1B (CMT1B). It has been documented that the severity of some truncating alleles in CHN and DSN is owing to dominant-negative effects, whereas the reduced severity of truncating alleles in CMT1B is owing to loss-of-function. In essence, for PTC mutations in which the mRNA is degraded by NMD, this enables the conversion of dominant-negative or gain-of-function effects to haploinsufficiency (Table 2) . Nevertheless, for selected genes such as MPZ, the PTC mutations that escape NMD may not always cause severe disease. Rather, the ultimate phenotype depends on the properties of the mutant proteins.
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NMD can modify phenotypes conveyed by allelic truncating mutations
The potential beneficial role of NMD is illustrated by genetic disorders whereby mutations usually convey a recessive trait, but can cause dominant diseases when the mutant transcripts escape NMD, and by disease genes in which toxicity of a mutant protein is mitigated by prevention of translation of the aberrant mRNA. However, NMD may also play a more subtle role in modulating ultimate disease expression. Missense mutations associated with the gene encoding the a chain of type XI collagen (COL1A1) and type II collagen (COL2A1) are classic examples of dominant-negative alleles as they disrupt the hetero-or homo-trimer confirmation of collagen subunits and are associated with severe disease phenotypes of osteogenesis imperfecta (OI) type II -IV and spondylepiphyeal dysplasia, respectively. In contrast, all truncating mutations in both genes have been shown to result in haploinsufficiency owing to NMD and are associated with the milder clinical phenotypes of OI type I by 5 0 PTC COL1A1 40, 41 and Stickler syndrome by 5 0 PTC COL2A1. 42 In both genes, a role for NMD in the ultimate disease phenotype has been postulated; however, experimental studies verifying such a mechanism for these mutant genes (ie that NMD mitigates the dominant-negative effect of the truncated proteins) have not been published. The extent of the beneficial effect may vary depending on both the toxicity of truncated proteins encoded by different genes and the nature of traits. Rarely, in some instances (Table 3) , PTCs triggering NMD may result in more severe diseases by abrogating the hypomorphic function of a mutant protein as illustrated by nonsense mutations in HEXA causing Tay -Sachs disease and the hemizygous X-linked Duchene muscular dystrophy (DMD) gene mutated in muscular dystrophy. Eight frameshift mutations in HEXA resulting in early PTCs susceptible to NMD have been found in 80% of the carriers of the severe form of Tay -Sachs disease from the Ashkenazi Jewish population. 43 Whereas the majority of disease-causing mutations in HEXA are associated with the severe form of Tay -Sachs disease, rare missense mutations with some residual activity result in a less severe form of this disorder. Although there has not been any study showing these truncating mutants retain residual activity when NMD is inhibited, the lack of HEXA mRNA owing to NMD can have a detrimental effect in this disorder. The rare truncating mutations that occur near the 3 0 end of dystrophin gene result in variable mild phenotypes, suggesting that these truncating proteins are capable of a partial rescue of the DMD phenotype. 44 The 5 0 PTCs, however, are associated with a severe form of DMD and fail to rescue the phenotype because of the NMD pathway. Evidence that NMD can increase the severity of DMD is a phenotypic rescue of the mouse model of DMD by using the cDNA transgene that encodes a dystrophin with C-terminal truncating mutations. 45 In theory, the disruption of NMD might also be a logical means for therapy; 46 for example, in the rare DMD patients with C-terminal truncating mutations with residual activity. It is likely, however, that specific inhibition of NMD might result in undesirable side effects as it may do more harm than the disease by the production of other mutant proteins, such as those caused by possible translational errors of even normal transcripts or translation of truncated pseudogene products, resulting in cellular toxicity from synthesis of aberrant proteins. 16, 47 This has created a unique dependence of mammals on the key factors of NMD and its pathway for viability as is implied by the embryonic lethality caused by congenital suppression of NMD factors in mice and the utilization of the NMD pathway in the regulation of normal transcripts. 15 -18,47,48 
Conclusion
In humans, the role of NMD as a modifier of the phenotypic consequences of PTC is becoming more apparent. The identification and characterization of the NMD machinery has provided insight regarding the basic process and development of possible therapeutic reagents by modulating the NMD pathway. Nevertheless, it is important to demonstrate experimentally the role for NMD to enable accurate conclusions regarding phenotypic differences conveyed by truncating mutations. Ultimately, the phenotypic outcome depends on the function of mutant protein and escape from NMD does not necessarily result in a more severe phenotype.
One can predict that NMD may play a role in phenotypic heterogeneity when either distinct phenotypic traits or distinct modes of inheritance (ie dominant versus recessive) are conveyed by allelic truncating mutations. NMD must also be considered when in vitro protein functional assays of disease associated PTC mutation using cDNA truncating clones show a similar outcome for distinct mutations that convey divergent phenotypes. Experimentally, if suppressing important NMD factors, such as hUpf1 and hUpf2, that can inhibit the NMD pathway directly 16, 20, 47 results in different expression levels of truncated proteins, then NMD is likely the predominate mechanisms involved. However, each case requires careful experimentation to elucidate the pathogenic mechanisms. It is difficult to estimate the number of genetic diseases in which NMD provides a protective effect (ie partially mitigates the consequences of mutation) owing to phenotypic variability and limited clinical data in the literature for various genetic disorders. However, recent findings not only increase our understanding of the physiological role of NMD but also shed light into the pathogenesis of different aspects of the phenotypes of genetic diseases commonly influenced by NMD.
An important outcome of NMD studies is that many genetic diseases that were previously thought to be the result of dominant-negative mutations on the basis of functional assays may actually result from loss-of-function or haploinsufficiency in vivo because of NMD. 20 Considering NMD enables a more accurate in vivo genotypephenotype correlation for truncating mutations. However, triggering NMD does not always convert a dominantnegative or gain-of-function mutation into a null allele and result in a milder phenotype because some truncated mutant proteins may retain residual wild-type activity. Approaches to protect transcripts containing a premature stop codon from NMD could potentially be used as an alternative treatment for some patients with disease caused by PTC mutations. However, such a therapeutic approach may have other unwanted consequences. NMD likely evolved owing to its beneficial role in eliminating truncated proteins that may have harmful effects on the cells. Nonetheless, NMD must be considered when formulating and testing hypotheses concerning heterogeneous clinical outcomes for different mutations in the same gene. The potential effect of NMD is also important to consider when one encounters a truncating mutation and is attempting to provide the appropriate genetic counseling regarding disease prognosis.
